SS-31: Clinical Guide for Prescribing Practices
SS-31 (Elamipretide) is a mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane, stabilizing cardiolipin and improving electron transport chain efficiency. It has been investigated in clinical trials for mitochondrial myopathies, heart failure, and age-related mitochondrial decline.
Also Known As
How SS-31 Works
SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) is a cell-permeable tetrapeptide that concentrates greater than 1000-fold in mitochondria due to its interaction with cardiolipin, a phospholipid unique to the inner mitochondrial membrane [3]. By stabilizing cardiolipin structure, SS-31 optimizes the organization of electron transport chain supercomplexes (particularly complexes III and IV), improving electron transfer efficiency and reducing electron leak that generates superoxide radicals [3]. This mechanism simultaneously increases ATP production and decreases mitochondrial reactive oxygen species at their primary source [2].
Clinical Evidence
Phase I/II clinical trials by Stealth BioTherapeutics demonstrated that elamipretide improved 6-minute walk distance in patients with primary mitochondrial myopathy (MMPOWER trials), though the Phase III trial did not meet its primary endpoint [1]. A Phase II trial in heart failure with preserved ejection fraction (HFpEF) showed improvement in left ventricular end-diastolic volume after 4 weeks of treatment [2]. In Barth syndrome (cardiolipin remodeling defect), elamipretide showed meaningful clinical improvement in functional measures across multiple endpoints in a crossover trial [4]. Preclinical data consistently demonstrates cytoprotection in ischemia-reperfusion injury models across cardiac, renal, and neuronal tissues [3].
Clinical Uses
Patient Selection and Screening
Most appropriate for patients with documented mitochondrial dysfunction (elevated lactate, reduced exercise tolerance with mitochondrial testing) [1], primary mitochondrial myopathies, age-related sarcopenia with objective functional decline, and patients with exercise intolerance not explained by cardiopulmonary disease. Consider for patients with heart failure and preserved ejection fraction (emerging indication) [2]. Patients should have objective baseline functional testing (6-minute walk, VO2 max, or grip strength) to monitor treatment response [1]. Use caution in patients with renal impairment as elimination pathways are not fully characterized in this population.
Dosing and Administration
Subcutaneous injection: 20 to 40 mg daily, based on Phase II clinical trial dosing of elamipretide (40 mg SC daily was well-tolerated in the MMPOWER studies) [1]. Some compounding protocols use 5 to 20 mg daily or 3 to 5 times weekly for general mitochondrial optimization in non-myopathy patients. Treatment duration in clinical trials was 24 to 48 weeks [4]; clinical practice courses are typically 8 to 12 weeks with functional reassessment. Injection site rotation recommended (abdomen, thigh). Store reconstituted solution refrigerated and use within manufacturer-specified timeframe.
Route: Subcutaneous injection
Protocol notes: Administered via subcutaneous injection. Clinical trial dosing has varied; compounding protocols typically use 5-50mg daily or several times weekly.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
SS-31 occupies a unique position as the most mechanistically validated mitochondrial peptide with extensive clinical trial data (over 500 patients across Phase I through III) [1][4], which strengthens the evidence narrative for patient education and informed consent. While patient volume is modest (specialized mitochondrial dysfunction populations), per-patient revenue is high due to extended treatment courses and detailed functional monitoring. Practices with mitochondrial medicine or complex chronic fatigue programs can position SS-31 as a premium, evidence-based intervention that differentiates from less-validated longevity peptides [3].
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe SS-31 through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What makes SS-31 different from other longevity peptides?
What clinical trial data exists for SS-31?
References
- Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy (MMPOWER-3). Neurology. 2023;100(11):e1161-e1175.
- Sabbah HN, et al. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9(2):e002206.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
- Reid Thompson W, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021;23(3):471-478.
Related Peptides in Metabolic & Longevity
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe SS-31 Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe SS-31 Through Karpa